APS announces 2004 Distinguished Lectu...( (Central Nervous System Section) Lec...)

APS announces 2004 Distinguished Lecturer Awards

(Central Nervous System Section)
Lecture Presentation: "Signal Integration in the Central Nervous System" on April 20, 2004.

Jerome Dempsey, Ph.D. University of Wisconsin, Madison
Julius H. Comroe, Jr. Distinguished Lectureship (Respiratory Section)
Lecture Presentation: "Crossing the Apneic Threshold: Causes and Consequences" on April 18, 2004.

Bert O'Malley, M.D. Baylor College of Medicine
Solomon A. Berson Distinguished Lectureship (Endocrinology and Metabolism Section)
Lecture Presentation: "Signaling Through the Steroid Receptor Coactivators" on April 19, 2004.

Gary Owens, Ph.D. University of Virginia School of Medicine
Robert M. Berne Distinguished Lectureship (Cardiovascular Section)
Lecture Presentation: "Molecular Regulation of Smooth Muscle Differentiation in Development and Disease" on April 19, 2004.

Christopher Wilcox, M.D., Ph.D. Georgetown University Medical Center
Ernest H. Starling Distinguished Lectureship (Water and Electrolyte Homeostasis Section)
Lecture Presentation: "Oxidative Stress and Functional NO Deficiency in the Kidney: A Critical Link to Hypertension?" on April 20, 2004.

John G. Forte, Ph.D. University of California, Berkeley
Horace W. Davenport Distinguished Lectureship (Gastrointestinal Section)
Lecture Presentation: "The Gastric Hydrogen Ion Cycle" on April 19, 2004.

V. Reggie Edgerton, Ph.D. University of California, Los Angeles
Edward F. Adolph Distinguished Lectureship (Environmental and Exercise Physiology Section)
Lecture Presentation: "Learning and Memory in the Spinal Cord" on April 20, 2004.

'"/>

Contact: Stacy Brooks
sbrooks@the-aps.org
301-634-7253
American Physiological Society
15-Apr-2004

Page: 1 2 3
Related biology news :

1. Secretary of Energy announces seven E.O. Lawrence Award Winners
2. Popular Science announces Third Annual Brilliant 10
3. The American Phytopathological Society announces 2004 awards
4. NSF announces six FIBR awards to tackle some of biologys most challenging questions
5. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
6. JGI announces community sequencing program portfolio
7. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
8. National Corn Growers Association announces valuable maize genome data now available to scientists
9. DFG announces three percent budget increase
10. Chemical Society announces EPA awards for environmentally friendly technology
11. Nanosphere announces genetic detection advance in Nature Biotechnology

Post Your Comments:

(Date:11/23/2009)...Washington, D.C. The community-associated strain ...cteria resistant to most common antibioticsposes a...nd is making its way into hospitals, according to ...ous Diseases . , The new threat is easily picke... places and has increased the overall burden of MR...

(Date:11/23/2009)... TORONTO, November 23, 2009 - The time of day mat...ng to a new paper produced by a research team led ...to Scarborough,s vice-principal for research and c...ology at the St. George campus. , Capitalizing...e poplar tree, the research team examined how popl...

(Date:11/23/2009)...IRVINE, Calif. -- More than 160 participants gathe...emies Keck FUTURES INITIATIVE conference. This yea...cientists, engineers, and medical researchers to e...ues surrounding the emerging field of synthetic bi...ar biology at Princeton University and this year,s...

Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2 Time of day matters to thirsty trees, U of T researcher discovers 2 Synthetic biology offers new opportunities for interdisciplinary collaboration 2 Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 1 Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 2 Hard To Treat Diseases 28HTDS PK 29 To Regain Intellectual Property 28IP 29 Ownership 49873 1 Hard To Treat Diseases 28HTDS PK 29 To Regain Intellectual Property 28IP 29 Ownership 49873 2 Hard To Treat Diseases 28HTDS PK 29 To Regain Intellectual Property 28IP 29 Ownership 49873 3 One Mans Mission to Improve Our Healthcare System and Resolve Chronic Pain 49871 1 One Mans Mission to Improve Our Healthcare System and Resolve Chronic Pain 49871 2

[2] New study finds MRSA on the rise in hospital outpatients [1] Time of day matters to thirsty trees, U of T researcher discovers [0] Synthetic biology offers new opportunities for interdisciplinary collaboration

(Date:11/23/2009)...v. 23, 2009 In a provocative new study, a Univers...oxide emissions the major cause of global warming...collapses or society builds the equivalent of one ...nlikely that there will be any substantial near-te...n carbon dioxide emission rates," says the new pap...

(Date:11/23/2009)...N,Nov.23/PRNewswire-FirstCall/-YMBioSciencesInc.(N...entcompanythatidentifiesandadvancesadiverseportfol...ofdevelopment,todayreportedthatCytopia(ASX:CYT)has...87,apotent,orally-administeredJAK1/JAK2inhibitor.T...nesota.AproposaltomergeCytopiaintoYMhasbeenpreviou...

(Date:11/23/2009)...Calif.,Nov.23/PRNewswire/--Frost&Sullivan,theG...fordemonstratingleadershipandinnovationThursday,No...AwardsBanquetheldinSanAntonio,Texas. ,, (Logo: ...O ) ,, TheHealthcareInnovationAwardsaregiventoc...eliveryandmanagementofhealthcare.Suchcompanieshave...

(Date:11/20/2009)... Nov. 20 Veridiam (www.veridiam.co...ze company category at the 2009 Workplace Excellen...go Society for Human Resources Management and reco...ractices. ,, Veridiam was one of nine winners, ...panies, honored at the recent awards ceremony. San...

Breaking Biology Technology:Is global warming unstoppable? 2 Is global warming unstoppable? 3 Is global warming unstoppable? 4 YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2 YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3 YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4 Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2 Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3 Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2

[0] Is global warming unstoppable?[0] YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA [0] Excellence in Healthcare Innovation Recognized by Frost & Sullivan [1] Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category

Other News:

...hen smog ozone is taken up by the forests of the S...lants. But new research at the University of Calif...e ozone is actually transformed by chemical reacti...t.......The new findings, published online in Apri...

...at is key to natural disease resistance in plants ...mpson Institute for Plant Research (BTI) and at Co...ncing the activity of the enzyme they might be abl...ts without resorting to pesticides or the introduc...

...alf of all individuals implanted with pacemakers s...one such patient reveals a previously unknown muta... rhythmicity of the beating heart.... ...TITLE: Pa...s node disease......CONTACT:...Schulze-Bahr, Eric....

... RNA, the blueprint for proteins. A special form o...cleans up the mess. Dutch researcher Sharief Baren...l catalyst for the functioning of tmRNA.......Mess...lt of damage. Ribosomes that translate damaged mRN...

New clues emerge about the fate of smog in Sierra Nevada forests 2 New clues emerge about the fate of smog in Sierra Nevada forests 3 Critical early-defense trigger in plants found 2 Critical early-defense trigger in plants found 3 JCI table of contents, May 15, 2003 2 JCI table of contents, May 15, 2003 3 JCI table of contents, May 15, 2003 4 JCI table of contents, May 15, 2003 5 JCI table of contents, May 15, 2003 6 Small protein helps special RNA make repairs 2

New clues emerge about the fate of smog in Sierra Nevada forests Critical early-defense trigger in plants found JCI table of contents, May 15, 2003 Small protein helps special RNA make repairs

Atlanta, Georgia, July 26, 2005 - UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinica

...acteria which can grow on and 'mop up' smelly comp...These smelly, highly reactive 'one-carbon' compoun...lphur-containing amino acids in the mouth.......Dr...don, reported these findings in the August issue o...

...nt for nerve damage caused by diabetes could bring...rts.......The treatment might also reduce the numb...s on nerve protection and regeneration are borne o...or cause of non-traumatic lower limb amputations i...

... has changed since it was originally posted..........l (MGH) researchers announced surprising findings ...s of mammalian reproductive physiology retained t...dulthood. Now the same investigators report new d...

Certolizumab pegol demonstrates positive results in two Phase III Crohn's disease trials 2 Diabetic nerve therapy shows 'striking' results 2 Bone marrow may be source of new egg-cell generation in adult mammals 2 Bone marrow may be source of new egg-cell generation in adult mammals 3 Bone marrow may be source of new egg-cell generation in adult mammals 4 Bone marrow may be source of new egg-cell generation in adult mammals 5

Certolizumab pegol demonstrates positive results in two Phase III Crohn's disease trials Bacteria feed on smelly breath (and feet)Diabetic nerve therapy shows 'striking' results Bone marrow may be source of new egg-cell generation in adult mammals